| Bioactivity | Bet-in-23 (Compound 23) is a BD2-selective BET inhibitor with an IC50 of 2.9 nM. BET-IN-23 has anticancer activity and can significantly inhibit the proliferation of acute myeloid leukemia (AML) cell lines by inducing G0/G1 arrest and apoptosis in vitro[1]. |
| Target | IC50: 2.9 nM (BET). |
| Name | BET-IN-23 |
| CAS | 2953287-57-3 |
| Formula | C29H34FN3O5 |
| Molar Mass | 523.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiang W, et al. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. J Med Chem. 2024 Jan 4. |
BET-IN-23
CAS: 2953287-57-3 F: C29H34FN3O5 W: 523.60
Bet-in-23 (Compound 23) is a BD2-selective BET inhibitor with an IC50 of 2.9 nM. BET-IN-23 has anticancer activity and c
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.